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Background: Familial glucocorticoid deficiency (FGD) is a rare autosomal recessive disorder that is characterized
by isolated glucocorticoid deficiency. Recently, mutations in the gene encoding for the mitochondrial nicotin-
amide nucleotide transhydrogenase (NNT) have been identified as a causative gene for FGD; however, no NNT
activities have been reported in FGD patients carrying NNT mutations.
Methods: Clinical, biochemical and molecular analyses of lymphocytes from FDG homozygous and heterozygous
carriers for the F215S NNT mutation were performed.
Results: In this study, we described an FGD-affected Japanese patient carrying a novel NNT homozygousmutation
(c.644TNC; F215S) with a significant loss-of-function (NNT activity = 31% of healthy controls) in peripheral
blood cells' mitochondria. The NNT activities of the parents, heterozygous for the mutation, were 61% of the
controls.
Conclusions: Our results indicated that (i) mitochondrial biogenesis (citrate synthase activity) and/or mtDNA
replication (mtDNA copy number) were affected at ≤60% NNT activity because these parameters were affected
in individuals carrying either one or both mutated alleles; and (ii) other outcomes (mtDNA deletions, protein
tyrosine nitration, OXPHOS capacity) were affected at ≤30% NNT activity as also observed in murine cerebellar
mitochondria from C57BL/6J (NNT−/−) vs. C57BL/6JN (NNT+/+) substrains.
General significance: By studying a family affected with a novel point mutation in the NNT gene, a gene–dose
response was found for various mitochondrial outcomes providing for novel insights into the role of NNT in
the maintenance of mtDNA integrity beyond that described for preventing oxidative stress.© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Familial glucocorticoid deficiency (FGD) is a rare autosomal reces-
sive disorder that is characterized by isolated glucocorticoid deficiency
[1] reported for the first time in 1959 [2]. The diagnosis of FGD is
based on clinical findings with patients usually presenting hypoglyce-
mia, seizures, jaundice, hyperpigmentation, failure to thrive, muscle
weakness and frequent or severe infections. The biochemical findings
are a markedly elevated plasma ACTH in the presence of low cortisol).
d both are considered as first
. This is an open access article underbut with a preserved mineralocorticoid production and a characteristic
ACTH insensitivity [3–15]. The long-term neurological consequences of
FGD can vary from learning difficulties, mild dementia [6], spastic quad-
riplegia [16,17], whichmay reflect the severity and number of hypogly-
cemic episodes during childhood [17]. Although this disease is easily
treatable when recognized, hypoglycemic attacks and convulsions
may result in coma or even death [18].
FGD has been identified with mutations in the melanocortin-2 re-
ceptor gene (MC2R) (~25% of patients), the MRAP gene encoding the
MC2R accessory protein (~20% of patients), the steroidogenic acute reg-
ulatory gene (STAR; ~5% of patients), and by a single mutation in the
mini-chromosome maintenance-deficient 4 homolog gene (MCM4) in
the Irish Traveler population [reviewed in ref [15]]. Although half of
the FGD cases are caused by mutations in genes involved in (i) thethe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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replicative complex critical for normal DNA replication and genome sta-
bility (MCM4), and (iii) antioxidant system (TXNRD2) [19], no muta-
tions have been found in the rest of the cases, suggesting the presence
of hitherto unidentified responsible genes in FGD. Recently, mutations
in the NNT gene, encoding the mitochondrial nicotinamide nucleotide
transhydrogenase (NNT), have been identified as a causative gene for
FGD [20]. Although a clear link between glucocorticoid deficiency and
NNT deficits has not been presented yet, it can be hypothesized that
the reducing equivalents required for the synthesis of glucocorticoids
via the adrenodoxin oxidoreductase system could be supplied by NNT
given the mitochondrial localization. The adrenodoxin oxidoreductase
comprises a short electron transport chain that provides reducing
equivalents for biosynthesis of iron–sulfur clusters ([21]) and steroid
hormones [22–24], serving as the first electron transfer protein in all
themitochondrial P450 systems, including cholesterol side chain cleav-
age in all steroidogenic tissues, steroid 11-beta hydroxylation in the ad-
renal cortex, 25-OH-vitamin D3-24 hydroxylation in the kidney, and
sterol C-27 hydroxylation in the liver (Eq. (1)):
2 oxidized adrenodoxin þ NADPH→ 2 reduced adrenodoxin þ NADPþ:
ð1Þ
NNT is located at the inner mitochondrial membrane of eukaryotes
and in bacteria. Under physiological conditions, this transporter gener-
ates reduced nicotinamide adenine dinucleotide phosphate (NADPH)
and NAD+ from NADP+ and NADH in the mitochondrial matrix fueled
by the proton gradient [25–27] (Eq. (2)).
Hþout þ NADH þ NADPþ→Hþin þ NADþ þ NADPH: ð2Þ
The direction of proton movement is the same as that for the
F1FO-ATP synthase, where Δp favors the forward reaction (left to
right; the Keq for the non-energy linked NNT activity is 0.79 and that
of the energy-linked is 480 [28,29]). The apparent equilibrium shifts to-
wards NADPH formation through a conformationally-driven mecha-
nism [26]. NNT activity in rat brain has been estimated to account for
~40% of the total cellular supply of NADPH, with the remainder provid-
ed by the pentose phosphate pathway, malic enzyme and NADP-
dependent isocitrate dehydrogenase [30].
NADPH is a co-substrate for glutathione reductase (GR) and
thioredoxin reductase [30–33]. These enzymes are part of an important
antioxidant defense mechanism that catalyzes the reduction of lipid
peroxides or hydrogen peroxide to the corresponding alcohol or
water, preventing the formation of other, more reactive oxygen species
(ROS) such as hydroxyl or hydroperoxyl radicals [31]. Loss of NNT activ-
ity in a variety of biological models is associated with a lower supply of
mitochondrial NADPH, increased mitochondrial ROS production and
decreased [GSH]/[GSSG] ratio [34], making mitochondria more suscep-
tible to ROS-induced damage [20,34,35]. A substrain of C57BL/6J mice,
carrying a spontaneousmissense (M to T)mutation in themitochondri-
al leader sequence of NNT coupled with an in-frame five exon deletion
removing four putative transmembrane helices [36], results in an al-
most negligible NNT activity [37] exhibiting a phenotype consistent
with FGD [20]. In addition, these mice show an impaired glucose ho-
meostasis and insulin release from β-cells by high glucose compared
to other mouse strains [36,38] and altered susceptibility to diet-
induced obesity [39]. Adrenal glands from these mice have increased
cellular apoptosis in zona fasciculata and compromised basal and stim-
ulated corticosterone levels [20].
Taken together, these reports suggest that losses in NNT activity
could result in (i) a defective response to cope with oxidative stress,
(ii) deficits in mitochondrial NADPH production which, depending on
the tissue, will lead to a defective steroidogenesis, and (iii) a combina-
tion of both effects. However, there are two significant aspects of this
field that have not been studied in detail. One, despite the 21 differentNNTmutations reported in 15 kindredwith FGDpredicted to significant-
ly alter either the targeting of NNT tomitochondria or its activity [15], no
direct functional studies of NNT activity have been performed in FGD
patients carrying NNTmutations. Thus, a clear correlation between ge-
notype–phenotype has not been explored. The other issue is that in-
creases in biomarkers of oxidative stress observed in some NNT-
deficient biological models may have obscured the role of NNT as an
NADPHprovider for relevant pathways other than those copingwith ox-
idative stress such as mitochondrial DNA (mtDNA) replication.
In this regard, mtDNA replication and maintenance require the pres-
ence of a suitable dNTP pool, especially dTTP [40–42], whose synthesis
depends on 3 enzymes, serine hydroxymethyltransferase-2, thymidylate
synthase and dihydrofolate reductase (DHFR), in which the last one is
NADPH- and folate-dependent. Rats fed a folate-deficient diet for
2 weeks showed significant increases in the mtDNA4834 deletion in lym-
phocytes [43]. By 4 weeks, increases in mtDNA copy number in lympho-
cytes and skeletal muscle [43], increased hepatic oxidative stress, lower
CCO activity (by 30%) and increased mitochondrial depolarization [44]
were reported. Deficiencies in perinatal folate intake have been reported
in mothers of children with autism [45] in which also abnormalities in
their mtDNA copy number have been observed [46].
Considering these two relevant issues not fully addressed in the lit-
erature, we studied a Japanese family in which the FGD-affected patient
has a novel homozygous substitution (c.644TNC; F215S) at exon 5 in
NNT [47]. In silico analysis predicted that F215S substitution has the po-
tential to disrupt the NAD binding site, decreasing NNT activity to levels
that could reach pathological consequences; however, the impact of this
mutation on NNT activity, ROS-mediated damage, and effect on mtDNA
replication has not been reported in this or in any other cases of FGD.
The aim of this study was to assess (a) the activity of NNT in lympho-
cytes from this patient and his parents, which are homozygous and het-
erozygous carriers for this point mutation, respectively, and (b) the
putative impact of this mutation on cellular oxidative/nitrative stress
and mtDNA replication.
2. Material and methods
2.1. Subjects
The patient's and parents' genotyping has been published before
[47]. The patient (male, 21 y at the time of blood sample collection)
was clinically diagnosed with FGD at 19 months of age based on
(i) hyperpigmentation, (ii) primary hypocortisonismwithout increased
17-OH progesterone, (iii) no definitive mineralocorticoid deficiency,
and (iv) normal male sex development. Mutation analysis performed
at the age of 17 y revealed that this patient carries a homozygous
F215S mutation in NNT [47]. Proband's mother (52 y) and father
(57 y), with no FGD, are both heterozygous for this mutation. This sub-
stitution was absent from 120 Japanese control subjects and was not
registered in public databases including Japanese SNP Database
(http://snp.ims.u-tokyo.ac.jp/). The patient is under oral hydrocortisone
replacement therapy. Adrenocorticotropic hormone (ACTH) levelswere
5.0, 7.4 and 19.6 pg/ml for patient (under glucocorticoid replacement
therapy), father and mother, respectively.
Blood lactic acid [10.8 mg/dl (4–17)], and lactic acid-to-pyruvate
ratio were within normal range [10.8 (b15)]. For this study, peripheral
lymphocytes from the patient and his parents were studied. Four of
the samples used as controls for NNT activity, NNT protein expression,
nitrated tyrosine, and cytochrome c oxidase activity were from race-
and sex-matched individuals, in which 2 matched the age of the
proband (25 and 29 y old) and the other 2 matched the parents' age
(54 and 58 y old) and sex. Data from 50 healthy individuals were
used for the comparison of citrate synthase activity, mtDNA copy num-
ber and mtDNA deletions. Informed consent was obtained in all cases.
This study was approved by the Institutional Review Board Committee
at Hamamatsu University School of Medicine.
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Adult [55] C57BL/6NJ and C57BL/6J (6–7 month old) mice were ob-
tained from Jackson Laboratories (Sacramento, CA). All procedureswere
conducted in strict compliance with the policies on animal welfare of
the National Institutes of Health and the University of California at
Davis (stated in the “Guide for the Care and Use of Laboratory Animals,”
Institute of Laboratory Animal Resources, National Research Council,
1996 edition), and approved by the University of California at Davis
Animal Care and Use Committee.
2.3. Genotyping mice for NNT
All mice utilized in this study were genotyped for the wild-type or
mutated NNT as described [39]. Genomic DNA was isolated from 5 mg
of hindbrain as previously described [56]. Concentration and purity of
DNA was measured at an absorbance of 260 nm and 280 nm on a
Tecan infinite M200 Nanoquant (Tecan, Austria).
2.4. Chemicals and biochemicals
Tris, EDTA, HEPES, MOPS, NaCl, palmitoylCoA, rotenone, sucrose,
3-acetylpyridine adenine dinucleotide (APAD), and β-NADPH were all
purchased from Sigma (St. Louis, MO). All reagents were of analytical
grade or higher.
2.5. Isolation of mitochondria-enriched fraction from human
peripheral lymphocytes
Peripheral lymphocyteswere isolated from10-ml of venous blood of
each subject collected with heparin under standardized conditions
using Lymphoprep density gradient centrifugation (Axis-Shield, Oslo,
Norway). Collection of lymphocytes was performed by aspiration,
and resuspending them in cryopreservation solution (CELLBANKERTM
1 Nippon Zenyaku Kogyo Co., Ltd, Japan) containing DMSO and
newborn calf serum. Cell pellets were kept at −20 °C until analysis.
Mitochondrial membrane-enriched fraction was isolated as reported
by others with modifications [48]. Briefly, isolated lymphocytes were
washed with PBS and centrifuged at 300 g for 15 min, then suspended
at a ratio of 10 × 106/ml in a hypotonic medium (10 mM HEPES,
pH 7.6); after 4 min on ice, the suspension was centrifuged at 1500 ×g
for 10 min at 4 °C. The supernatant was centrifuged at 10,000 ×g for
20 min to precipitate mitochondrial membranes. These mitochondrial
enriched-membrane proteins were resuspended in 200 μl of 0.25 M su-
crose, 2 mM EDTA, pH 8.0 and kept at−20 °C until analysis.
2.6. Non-energy linked NNT activity
Spectrophotometric assessment of NNT activity was performed es-
sentially as described by others [49,50]. The reaction mixture was com-
posed of 50 mM Tris (pH 8.0), 300 μM APAD (3-acetylpyridine adenine
dinucleotide; Sigma-Aldrich), an analog of NAD+, 300 μM β-NADPH
and 10 μM rotenone. APADwas used instead of NAD+ because this com-
pound has a different absorption spectrum fromNADPH andNADH. The
reactionwas initiated by the addition of 100–150 μg homogenizedmito-
chondrial enriched-membrane proteins (20 μl) obtained by 3 cycles of
freeze–thawing followed by a 5-s sonication with a Fisher 550 sonic
dismembrator (intensity 2.5) [51]. Changes in absorbance were moni-
tored at 375 nm for 3 min. Rates of NNT were converted to nmol APAD
reduced/min using the extinction coefficient (5.1 mM−1 × cm−1) and
normalized to protein, which was determined using the BCA assay. To
provide experimental controls for NNT-mediated APAD reduction, ho-
mogenized mitochondria were incubated for 5 min with 1 mM
palmitoylCoA, competitive inhibitor of NNT [52].2.7. Evaluation of mitochondrial enzymatic activities
Evaluation of mitochondrial enzymes was carried out in either total
human lymphocyte homogenates or in mouse mitochondria isolated
from cerebellum by differential centrifugation as previously described
[57,58]. Activities of NQR (Complex I), CCO (Complex IV), ATPase and
citrate synthase were evaluated as described before using a Tecan Infi-
nite M200 microplate reader [53].
2.8. Evaluation of mtDNA copy number and deletions
Genomic DNAwas isolated from either human cell pellets (0.6 × 106
cells) or murine cerebellum using the Gentra Puregene Cell and Tissue
Kit (Qiagen cat no: 158388) following themanufacturer's recommenda-
tions for body fluid samples and tissue samples respectively [46,56].
Purity of DNA, measured at 260 nm and 280 nm on a Tecan infinite
M200 Nanoquant (Tecan, Austria), was N1.9 for all samples. Following
DNA extraction, changes in mtDNA copy number and deletions were
evaluated as described in details elsewhere [46,56]. Relative mtDNA
copy number per cell was assessed by a comparative Ct method, using
the following equation: mtDNA/nDNA = 2−ΔCt, where ΔCt =
Ctmitochondrial− Ctnuclear. Each sample was analyzed in triplicates. The
gene copy number of cytochrome ND1 was normalized by a single
copy nuclear gene (pyruvate kinase) to reflect themtDNA copy number
per cell whereas the ratios of CYTB or ND4 copy number normalized to
that of ND1 reflected mtDNA deletions.
2.9. Protein determination
Protein evaluation in samples was performed with the Pierce BCA
protein assay (Thermo Scientific, Waltham MA).
2.10. Western blotting
Western blotting procedures were performed essentially as de-
scribed before [53,54] with the modifications indicated below. Protein
extracts from total cell homogenates were concentrated and partly
delipidated by acetone precipitation, through the addition of 4 volumes
of−20 °C acetone to each homogenate. Acetone-containing mixtures
were vortexed and placed at−20 °C for 24 h. Sampleswere then centri-
fuged at 16,000 ×g for 10min at 4 °C. After pouring off the supernatant,
the pellet was resuspended and washed two more times with−20 °C
acetone, spinning each wash at 16,000 ×g for 10 min at 4 °C. After re-
moving the supernatant from the final wash, the samples were placed
in the SpeedVac for 15 min to remove residual acetone. Samples
were resuspended in RIPA buffer (25 mMMOPS, 150 mM NaCl, 1 mM
EDTA, 1% NP-40, 0.1% SDS, 1% DOC, pH 7.5) and the protein concentra-
tion was evaluated using a BCA Protein assay kit (Pierce #23227).
Proteins pelletswere denatured inNuPAGE sample buffer (Life Technol-
ogies) plus 50 mM DTT at 70 °C for 10 min. Forty μg of protein was
added to successive lanes in the SDS-PAGE, transferred via iBlot system
(Life Technologies) to a 0.2-μmPVDFmembrane for 7min (program 3).
Membranes were washed once for 5 min in Tris buffered saline, follow-
ed by blocking in Odyssey Blocking Buffer (LI-COR # 927-40000) for 1 h
and then incubated with primary antibodies to COXIV (Cell Signaling,
1:1000), GAPDH (Proteintech, 1:1000), NNT (Proteintech, 1:750), and
nitrotyrosine (Millipore, 1:1000), overnight at 4 °C. Membranes were
washed 4 × for 5 min with TBST (150 mM NaCl, 25 mM Tris, pH 7.4,
0.1% Tween-20) and then incubated with IRDye 800CW goat anti-
rabbit antibody (LI-COR) or 680 goat anti-mouse antibody (LI-COR),
diluted 1:10,000 for 1 h at room temperature. After washing the
membranes 3× for 10 min with TBST, proteins were visualized with
an Odyssey infrared imaging system (LI-COR). Images were analyzed
with the Odyssey V3.0 software and the band intensities expressed as
arbitrary fluorescence units (AFU).
Table 2
Mitochondrial outcomes in cerebellar mitochondria from NNT−/− and NNT+/+ mice.
Outcome NNT+/+ NNT−/− p-Valuea
Citrate synthase activity 280 ± 10 200 ± 1 b0.05
NQR/CS 0.45 ± 0.08 0.21 ± 0.02 0.05
CCO/CS 0.34 ± 0.02 0.29 ± 0.02 0.05
ATPase/CS 3.3 ± 0.6 2.14 ± 0.07 0.05
mtDNA copy number/cell 273 ± 10 133 ± 4 b0.001
mtDNA deletions
CYTB/ND1 (%)
b1 30 ± 4 0.004
ND4/ND1 (%) b0.5 9 ± 2 0.004
Citrate synthase, NQR, CCO and ATPase activity were all expressed as nmol × (min × mg
protein)−1, and the last 3, normalized to citrate synthase. Data are reported as mean ±
SEM of experiments ran in triplicates with tissues obtained from 4 NNT+/+ and 6 NNT−/−
mice. Mitochondrial DNA copy number and deletions were calculated as described in the
Material and methods section. The average CYTB/ND1 and ND4/ND1 control ratios were
taken as 100% (no deletions) andNNT−/−mitochondrial gene ratioswere expressed as per-
centages of controls. The differences between 100% and theNNT+/+ orNNT−/− percentages
were taken as the % of deletions for that particular mtDNA segment.
a The p-values were calculated by using the 2-tailed Student's t test and considered
significant if p b 0.05.
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Data frompatient and parentswere obtained fromat least duplicates
run on the same day. Other details were indicated under Tables 1 and 2.
2.12. Molecular modeling
The 3D structure of the NNT was obtained through modeling of the
mature, primary sequences of the human WT and F215S NNT [59,60]
as indicated before [61]. The 3D structure was further refined by using
ChemDraw. All pdb files were visualized using PyMol 1.4.1 [62].
3. Results
3.1. NNT activity in peripheral lymphocytes from carriers follows a
gene–dose response
The non-energy linked activity of NNT was evaluated in
mitochondria-enriched fractions from lymphocytes obtained from a
21 y old patient (carrying a homozygous F215S NNT mutation), his par-
ents (heterozygous for this mutation) and controls. The NNT activity
values from control (regardless of age or sex) in peripheral lymphocytes,
expressed per mg of mitochondrial protein, were 27 to 62 nmol ×
(min × mg)−1, consistent with those reported before for mitochondria
from tissues with relatively low endogenous NNT activity [e.g., prostate,
seminal vesicles, spleen, and testis [63]] and within values of other solu-
bilized mitochondrial transhydrogenases [30–80 nmol × (min × mg
protein)−1 [64–66]]. No difference in NNT activity was observed be-
tween younger and older controls (respectively 1.31 ± 0.05 and
2.05 ± 0.5; p=0.177). The NNT specific activity [defined as the activity
expressed as nmol product × (min× 106 cells)−1 normalized by theNNT
protein levels] in the patient's samplewas 31% of themean control value
and 56% of his parents (Table 1), both values outside the 95%CI. The av-
erage NNT activity of the parents was not different from each other but,
in both cases, lower than controls average (61% of controls). Thus, these
results indicated that the decrease in NNT activity followed a gene–dose
dependency.
To visualize the F215S mutation in the NNT protein, the mature and
mutated proteins were modeled in silico (Fig. 1A). From the 4 full pri-
mary sequences of NNT (human, mouse, bovine and rat) available in
the protein database, F215 is present in a highly conserved segment
not part of the predicted NAD binding site (residues 229–259). How-
ever, the phenyl ring is facing a hydrophobic pocket lined with Ala, Ile,
and Leu residues, which should bind part of the NAD moiety. WhenTable 1
Mitochondrial outcomes in lymphocytes from patient and controls.
Outcome Patient Mother Father
NNT activity/NNT protein levels
(×1000)
0.57 ± 0.02 1.00 ± 0.003 1.04 ± 0.03
Range [1.27, 2.40]
Nitrotyrosine (normalized by GAPDH) 10.1 ± 2.9 7.7 ± 3.0 6.2 ± 0.4
Range [3.4, 5.6] [4.3, 10.6]
Citrate synthase activity 2.1 ± 0.1 1.7 ± 0.1 4.6 ± 0.8
95%CI [6,12]
CCO/CS activity 1.8 ± 0.4 4.2 ± 0.5 2.3 ± 0.3
Range [2.1, 4.4]
Bold numbers indicate values outside either the 95%CI (calculated with control values) or
Range (when the number of control individuals for a particular outcomewas b4, the range
represents the lowest andhighest values obtained for that outcome).Whenno statistically
significant difference was observed between younger and older control individuals only
one combined 95%CI or range was reported instead of two. The 95%CI for citrate synthase
activity was calculated using data from healthy individuals aged 20 to 30 y (n= 38) and
40 to 60 y (n=12) that matched the age of the parents. NNT activity, CCO activity and CS
activity were all expressed as nmol × (min × 106 cells)−1. NNT activity was then normal-
ized to the intensity of the NNT band obtained by Western blots to express the specific
activity. AUD, arbitrary units of density of the nitrated protein band normalized to an un-
known protein used as loading control.F215 is replaced by S, new H-bonds are formed between S215 and the
adjacent T216, disrupting the H-bonds between residues 250–252. As
a result, changes in size and shape of this pocket occur, possibly affect-
ing the H+ transfer [26], and in turn its transhydrogenase activity.
Thus, the in silico analysis is consistent with the significant NNT activity
loss induced by the F215S mutation.
3.2. Increased nitrative stress in lymphocytes from FGD patient but not in
heterozygous carriers
Given the putative role of NNT at providing NADPH for several
processes including mitochondrial antioxidant defenses [35,37], the
oxidation/nitration of lymphocytic proteins was evaluated by Western
blotting using antibodies against nitrotyrosine. Tyrosine nitration was
mostly evident in the patient's lymphocytes at bands with MW of 55
and 58 kD (Fig. 1B). At these bands, protein nitration in the patient's
lymphocytes, expressed as arbitrary fluorescence units (AFU) and nor-
malized by GAPDH, was 10.1 ± 2.9 (mean ± SEM), 2.2-fold higher
than aged-matched control (p=0.04). In the father's andmother's lym-
phocytes, tyrosine nitration levels were 6.2± 0.4 and 7.7± 3.0, respec-
tively, within the range obtained with age-matched controls and not
different from the nitration observed in the proband's lymphocytes.
3.3. Lowermitochondrialmass inmutation carriers but lower OXPHOS only
in FGD-affected patient
In parallel experiments, to evaluate the effect of the NNTmutation
on themitochondria number and oxidative phosphorylation (OXPHOS)
capacity, we assessed the activities of citrate synthase, as a relatively
stable marker of mitochondrial mass [67], and cytochrome c oxidase
or Complex IV (CCO), the terminal oxidase of the electron transport
chain. The activity of citrate synthasewas lower in both patient and par-
ents compared to that in controls, regardless of age (20 to 30% of control
values; Table 1) suggesting a lower mitochondria number/cell. The ac-
tivity of Complex IV, normalized by citrate synthase, was significantly
lower in the patient's lymphocytes with no differences between that
in the parents and controls (Table 1). The protein expression values of
the subunit IV of CCO normalized to GAPDH for the patient and his par-
ents were within the 95% CI calculated with control values and, as such,
not different from controls (for COXIV/GAPDHmean ± SD= 5.1 ± 0.1
for the patient, 3.6 ± 0.1 for his parents; range for controls =
[1.3, 11.9]). Thus, these results suggested that the lower CCO activity
could not be attributed to a defective synthesis and/or import of the
nuclearly-encoded subunit IV and, possibly that of other nuclear DNA
(nDNA)-encoded mitochondrial proteins, but to a lower contribution
Fig. 1. A. In silico modeling of NNT structure. The 3D images were obtained through modeling of the mature primary sequences of the human wild-type (WT) and F215S mutant NNT
(MUT), as described in the Material and methods section (subsection 2.12). Protein backbone is in gray, amino acid of interest shown in blue and H-bonds are in yellow. 1B. Nitration
of tyrosine residues in lymphocytes. Representative Western blot image of proteins with nitrated tyrosine residues in lymphocytes from patient, his parents and age-matched controls
(C1 = patient's age-matched controls, 25 years old; C2 and C3 = parents' age-matched controls, 54 and 58 years old respectively). Western blots were carried out as described in the
subsection 2.5 of Material and methods. The lanes were loaded with equal cell concentrations and the densitometry of the nitrotyrosine bands was normalized by GAPDH. The results
of the quantification are shown in the lower panel. *p b 0.05 vs. C1. 1C. mtDNA copy number in lymphocytes from homozygous and heterozygous carriers and age-matched controls.
ThemtDNA copy number per cell and deletionswere estimated by qPCR as described underMaterial andmethods (subsection 2.9) and expressed as fold-change relative to the youngest
control (C1). ANOVA followed by Bonferroni post-hoc test: a, b = p b 0.01; c, d = p b 0.05. 1D. mtDNA deletions in lymphocytes from homozygous and heterozygous carriers and age-
matched controls. Deletions were evaluated at the segments encoding for CYTB (cytochrome b), and ND4 (NADH dehydrogenase subunit IV). Due to the limited amount of samples
from the parents, these samples were combined for the extraction of gDNA. As a result, the evaluation of mtDNA copy number and mtDNA deletions were performed on these pooled
samples. ANOVA followed by Bonferroni post-hoc test: a, e, f = p b 0.01; b, c, d = p b 0.05.
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subunits.
Taken together, these results suggested that the presence of at least
oneNNTmutated allele leads to a significant lower mitochondrial mass,
a situation that is enhanced specifically in the patient by the lower CCO
specific activity.
3.4. mtDNA copy number and deletions in FGD
Given theNADPH dependency of DHFR (andDHFRL1; [68]), enzyme
of the dTMP pathway required to maintain mtDNA integrity [40], the
mtDNA copy number per cell and mtDNA deletions were evaluated in
the patient's and his parents' compared to age-matched control lym-
phocytes (Fig. 1C and D).
The mtDNA copy number in the patient's lymphocytes was
56% lower than the mean values for age-matched controls (Fig. 1C),accompanied by mtDNA deletions at various segments of the mtDNA
(CYTB/ND1: patient = 0.77 ± 0.04, age-matched controls = 1.00 ±
0.09, p b 0.01; ND4/ND1: patient = 0.89 ± 0.04, age-matched con-
trols= 1.00± 0.01, p b 0.05). The extent of these deletionswas compa-
rable to that observed in individuals 30 years older than the patient,
including his parents (Fig. 1D). The parents' mtDNA copy number was
40% lower than themean age-matched control value (Fig. 1C); however,
themtDNAdeletions in the parents' lymphocyteswerewithin those ex-
pected for an older group (Fig. 1D). Of note, a statistically significant dif-
ference in mtDNA copy number was observed even between younger
and older controls, consistent with some findings reporting decreased
mtDNA copy number as an aging-related outcome [69,70].
The lower mtDNA copy number (as observed in patient and his par-
ents), lower mitochondrial mass (patient and his parents), and signifi-
cant increased mtDNA deletions (patient) compared to the increased
protein nitration (patient) seem to point to a phenotype different to
75Y. Fujisawa et al. / BBA Clinical 3 (2015) 70–78that solely defined by increased oxidative stress. Indeed, the mitochon-
drial outcomes of the patient were aligned to those reported for folate
deficiency in which deficits in OXPHOS and increased mtDNA deletions
have been observed [43,44,71]. Moreover, as reported for folate defi-
ciency [72], a lower peripheral lymphocytic yield was obtained in all
carriers compared to controls (range of controls 10 to 20 × 106 cells/
8–12 ml blood; for carriers in 106 cells: patient 8.2, father 4.5 and
mother 6.4). The lower lymphocyte yield observed in parents, relative
to the patient, could be explained by an age-dependent effect added
to the NNT heterozygosity.
3.5. Comparison of mitochondrial outcomes in FGD to a murine model of
NNT deficiency
To ascertain similarities between the patient and a murine model of
NNT deficiency, mitochondrial outcomes were evaluated in cerebella
from adult C57BL/6J [NNT−/− carrying a spontaneous NNT mutation
resulting in negligible NNT activity [37]] and C57BL/6NJ (NNT+/+)
substrains. Although other genetic differences have the potential to con-
tribute to the phenotypic differences between these substrains [39,73],
the loss of NNT activity in cerebellum from NNT−/−micewas accompa-
nied by a lower mitochondrial mass (as judged by CS activity; ~70% of
controls) as well as lower Complex I, IV and V activities normalized to
citrate synthase (in average by 34% of controls; Table 2). The mtDNA
copy number was significantly lower in NNT−/− (49% of control values;
Table 2) accompanied by significant increases deletions at the segments
encoding for CYTB (30%) and ND4 (9%). Thus, taken these resultsFig. 2.Molecular pathways linkingmutant NNT to oxidative stress, deficits inmitochondrial ene
of mitochondrial NADPH in eukaryotes. The NNT loss-of-function results in lower NADPH produ
decreased mtDNA integrity (copy number and deletions), and lower mitochondrial mass. We
synthesis. Deficits in dTTP could affect the maintenance of mtDNA integrity in the de novo th
and increasemtDNA deletions. Abbreviations: SHMT, DHFR, TYMS and TK are serine hydroxylm
spectively. DHF, THF, 5,10-MTHF are dihydrofolate, tetrahydrofolate and 5,10-methyl-tetrahydtogether, the mitochondrial outcomes observed in NNT−/−mice were
similar to those from the patient's lymphocytes, and both characterized
by lower mitochondrial mass, lower OXPHOS capacity and increased
mtDNA deletions.
4. Discussion
In this study, for the first time we characterized mitochondrial out-
comes in lymphocytes from a patient affected with FGD carrying a
novel, homozygous NNT F215S mutation. A mechanism linking defects
in NNT and glucocorticoids deficiency has not yet been established;
however, considering that NADPH-dependent mitochondrial processes
such as (i) ferredoxin reductase and ferredoxins for biosynthesis of iron-
sulfur clusters [13] and steroid hormones [22–24], and (ii) adrenodoxin
oxidoreductase, serving as the first electron transfer protein in all the
mitochondrial P450 systems (including cholesterol side chain cleavage
in all steroidogenic tissues, steroid 11-beta hydroxylation in the adrenal
cortex, 25-OH-vitamin D3-24 hydroxylation in the kidney, and sterol
C-27 hydroxylation in the liver [74,75]), it is conceivable that the reduc-
ing equivalents required for these processes are supplied by NNT.
Lymphocytes from the FGD patient analyzed in this study exhibited
a significant (by 70%) loss-of-function activity of NNT, consistent with
the lower H+ transfer predicted by the 3D protein model. The lower
NNT activity was accompanied by deficits in OXPHOS capacity, lower
mitochondrial mass, increased mtDNA deletions and increases in pro-
tein nitration. When the patient's outcomes were compared to his par-
ents', clinically healthy but heterozygous carriers for this mutation, thergy production and decreases inmtDNA integrity. NNT constitutes one of themain sources
ction, resulting in deficits in antioxidant defenses (via glutathione peroxidase/reductase),
hypothesized that NNT may act as the main provider of NADPH for de novo thymidylate
ymidylate biosynthesis, impairing the synthesis of dTMP required for mtDNA replication
ethyl transferase, dihydrofolate reductase, thymidilate synthase and thymidine kinase, re-
rofolate.
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genesis (citrate synthase activity) and/or mtDNA replication (mtDNA
copy number) are affected because these parameters were abnormal
in individuals carrying one or both mutated alleles; and (ii) ≤30%
NNT activity, deficits in other outcomes (mtDNA deletions, protein
nitration, OXPHOS capacity) are triggered in line with (a) the minor
diagnostic criteria for mitochondrial respiratory chain disorders [mito-
chondrial activities between 20 and 30%; [76]], (b) the results obtained
with murine cerebellar mitochondria from C57BL/6J (NNT−/−) vs.
C57BL/6JN (NNT+/+) substrains, and (c) those publishedwith negligible
NNT activities and increased oxidative stress [34].
Our results support the concept that proton-pumping transhydro-
genases constitute one of the main sources of mitochondrial NADPH
in eukaryotes (35 to 45% of the total NADPH is provided by both
NNT and the pentose phosphate pathway [30,77]), followed by the
NADP+-isocitrate dehydrogenase (20 to 25%) and the mitochondrial
NAD(P)+-malic enzyme [~10% [30,77–79]]. However, this role is not
only relevant to adrenocortical cells [15], but also to other cells (not nec-
essarily associated with steroidogenesis) where NNT is expressed to
varying degrees [80]. While most of the work in the field has highlight-
ed the involvement of NNT, directly or indirectly, in themaintenance of
antioxidant defenses [20,30,34,37,81,82], the apparent discrepancy be-
tween the NNT thresholds for mtDNA replication and/or mitochondrial
biogenesis and that for oxidative stress-mediated outcomes (protein ni-
tration,mtDNAdeletions) suggests that NNT is not the rate limiting step
in the ROS detoxification system [as glucose-6-phosphate dehydroge-
nase is in PC12 cells [83]], in which other NADPH sources overlap and
complement mitochondrial NADPH production [30,77–79]. In support
of this concept, it has been reported that tissues from NNT−/− mice
with no detectable NNT activity showed only a 33% decrease in
the [GSH]/[GSSG] ratio [37], indicating that the majority (~70%)
is accounted for by other NADPH sources. Moreover, the main in-
volvement of NNT as part of the antioxidant response has been chal-
lenged by the higher susceptibility of NNT+/+ mice vs. NNT−/− to
acetaminophen- and concanavalin A-induced liver injury [84] and to
cerulein-induced chronic pancreatitis [85], biological models of organ
injury inwhichmitochondrial oxidative stress seems to play a patholog-
ical role [86–89].
Then, the distinctions between homozygous and heterozygous car-
riers seem to originate from differences in either the NADPH threshold
for these processes or the rate of these reactions in vivo, i.e., the antiox-
idant response vs. mtDNA replication/repair pathway. The first alterna-
tive seems unlikely based on the relatively low Km of NADPH for both
glutathione reductase (5 to 25 μM [90–92]) and DHFR (or DHFRL1)
(3–4 μM [68]), even with a 30% residual NNT activity such as that ob-
served in the FGD patient reported in this study. Alternatively, NNT
may act as the main provider of NADPH for thymidylate synthesis
(Fig. 2). Deficits in dTTP could affect themaintenance of mtDNA integri-
ty in the de novo thymidylate biosynthesis, impairing the synthesis of
dTMP required for mtDNA replication [40,43,44,71,93] and increase
mtDNA deletions, as observed in mice lacking UNG undergoing folate
deprivation [71]. Indeed, the lower mtDNA copy number observed in
FGD could be explained by a prolonged replication pause [94] resulting
fromaltered nucleotide precursor pool asmtDNA instability increases in
the presence of a limiting dTTP pool as it has been reported for folate
deficiency [43,44,71,93]. In line with this reasoning, the deficiencies re-
ported in perinatal folate intake inmothers at risk of having a childwith
autism [45] could explain the differences in copy number and deletions
observed in peripheral blood cells in children with autism [46,95].
Considering that the mtDNA deletions observed in this patient with
a homozygousNNTmutationwere similar to those expected for individ-
uals 30 years older, it highlights the role that mtDNA cumulative
damage could have at enhancing and/or extending the morbidity of
FGD to symptoms observed inmitochondrial disorders (such as ketosis,
muscleweakness, progressive neurodegeneration), favored by deficient
antioxidant responses aided by the replicative advantage of large-scaledeletions [96,97], accumulation of mtDNA damage over time [69,70]
and by the decline in NNT gene expression with age [98]. Thus, from
the clinical point of view, it is important to emphasize the need for a
long-term systematic medical follow-up of FGD patients.
Finally, it is important to emphasize the parallel between this family
with a point mutation in NNT and that of a family with a homozygous
mutation inMCM4/PRKDC presenting FGD features and atypical Fanconi
type DNA breakage disorder [99]. These genes, shown to function in
mitochondria [100,101], are involved in the ataxia-telangiectasia-
mutated/ATM-Rad 3-related DNA repair pathway. Then pathogenic
mutations in NNT (this study), MCM4/PRKDC [99] and TXNRD2 [19]
highlight the morbidity of a dysfunctional mitochondrial antioxidant/
repair pathway in steroidogenic as well as in non-steroidogenic tissues.
Deficits in the mitochondrial antioxidant/repair pathway (along with
disease modifiers, such as genetic background and environmental trig-
gers) can contribute to themorbidity of the FGD syndrome as evidenced
by those clinical outcomes also shared by othermitochondrial disorders
[e.g., failure to thrive, recurrent infections; [15,76,103–105]]. It also indi-
cates thatmtDNAdamagemight be a commonpathological condition in
a subgroup of FGD patients with defective responses to DNA damage
[102].
5. Conclusions
This study provides for the first time an insight into the role of NNT
in themaintenance of mtDNA and underlines the relevance of assessing
NNT activity to predict its impact on mitochondrial outcomes to design
a rationale therapy that minimizes mitochondrial deficits while receiv-
ing supplementation with corticoids.
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